Structure Therapeutics Inc.
GPCR evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $2.88B
- Lead Asset:
- GSBR-1290 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for GPCR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GPCR
Structure Therapeutics Inc. (GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule GPCR-targeted therapies for metabolic and endocrine disorders, with its lead candidate aleniglipron (GSBR-1290) in Phase 2 for obesity and overweight.
Key risk: No product revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 20 clinical trials for Structure Therapeutics Inc..
Structure Therapeutics Inc. (GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule GPCR-targeted therapies for metabolic and endocrine disorders, with its lead candidate aleniglipron (GSBR-1290) in Phase 2 for obesity and overweight.
- Lead candidate aleniglipron (GSBR-1290) is an oral small-molecule GLP-1 receptor agonist in Phase 2 trials for obesity and overweight, with 36-week topline data from ACCESS and ACCESS II studies delivered in December 2025 [sec · filed 2026-04-23].
- Advanced oral amylin program ACCG-2671, a dual amylin and calcitonin receptor agonist (DACRA), into first-in-human Phase 1 study in December 2025 [sec · filed 2026-04-23].
- Cash, cash equivalents and short-term investments were $1,342.7 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Net loss was $106.2 million for the six months ended June 30, 2026 (from structured financials) [sec]; accumulated deficit was $652.4 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Closed an upsized underwritten public offering of American Depository Shares and pre-funded warrants totaling approximately $747.5 million in gross proceeds [sec · filed 2026-04-23].
What works
- Strong cash position of $1,342.7 million as of June 30, 2026, expected to fund operations for at least 12 months [sec_mda · as of 2026-08-06].
- Differentiated platform leveraging structure-based drug discovery and computational chemistry for GPCR targets, a class that includes approximately one in three marketed medicines [sec · filed 2026-04-23].
- Multiple clinical-stage assets: aleniglipron in Phase 2 with Phase 3 planning underway, and ACCG-2671 entering Phase 1 [sec · filed 2026-04-23].
- Received $100.0 million upfront license fee in Q1 2026 for patents covering a class of oral GLP-1 receptor agonists distinct from aleniglipron [sec_mda · as of 2026-08-06].
What to weigh
- No approved products and no product revenue generated to date; net losses of $182.1 million in the six months ended June 30, 2026 [sec_mda · as of 2026-08-06].
- Accumulated deficit of $652.4 million as of June 30, 2026, with expectations of continued significant operating losses [sec_mda · as of 2026-08-06].
- Will need substantial additional capital to fund Phase 3 trials of aleniglipron and other operations [sec_mda · as of 2026-08-06].
- Year-to-date share price decline of 45.96% as of September 22, 2026, indicating recent market skepticism [news · published 2026-09-22].
From the filings
Quoted directly from source documents.
Lead candidate aleniglipron is an oral small-molecule GLP-1 receptor agonist in Phase 2 for obesity.
“Our most advanced product candidate, aleniglipron (GSBR-1290), is an oral small molecule selective GLP-1 receptor agonist currently being evaluated in Phase 2 clinical trials for obesity, overweight and related conditions, and is being advanced into Phase 3 planning.”
SEC filings · April 23, 2026
Cash position as of June 30, 2026.
“As of June 30, 2026, we had cash, cash equivalents and short-term investments of $1,342.7 million.”
SEC MD&A · August 6, 2026
Net loss for six months ended June 30, 2026.
“We had net losses of $182.1 million and $108.5 million in the six months ended June 30, 2026 and 2025, respectively.”
SEC MD&A · August 6, 2026
Accumulated deficit as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $652.4 million.”
SEC MD&A · August 6, 2026
Risks & what to watch (4)›
Key risks
- No product revenue — No approved products and no product revenue generated; net losses continue [sec_mda · as of 2026-08-06].
- Capital needs for Phase 3 — Substantial additional capital required to fund Phase 3 trials of aleniglipron and operations [sec_mda · as of 2026-08-06].
- Clinical trial risks — Phase 2 data for aleniglipron and Phase 1 for ACCG-2671 may not support advancement [sec · filed 2026-04-23].
- Market skepticism — Year-to-date share price decline of 45.96% as of September 22, 2026 [news · published 2026-09-22].
What to watch
- Initiation of Phase 3 trials for aleniglipron and any additional data from ACCESS OLE and ACCESS II extension studies [sec_mda · as of 2026-08-06].
- Progress of ACCG-2671 Phase 1 study and potential Phase 2 initiation [sec · filed 2026-04-23].
- Cash runway updates: management expects existing cash to fund operations through at least mid-2027, but actual burn rate may vary [sec_mda · as of 2026-08-06].
- Any new financing or partnership deals, given the need for additional capital [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 5, 2026 · How we verify sources →
Run Structure Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Structure Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
195
Total value held
$3.14B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 8,403,449 | $405.0M |
| wellington management group llp | 7,260,287 | $349.9M |
| avoro capital advisors llc | 6,555,555 | $316.0M |
| janus henderson group plc | 5,354,981 | $258.3M |
| deep track capital, lp | 4,279,848 | $206.3M |
| bvf inc/il | 3,459,358 | $166.7M |
| morgan stanley | 2,305,457 | $111.1M |
| principal financial group inc | 1,753,764 | $84.5M |
| driehaus capital management llc | 1,577,356 | $76.0M |
| orbimed advisors llc | 1,475,403 | $71.1M |
Showing top 10 of 195 institutional holders of Structure Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 10.8%
- Days to cover
- 5.7
- Shares short
- 5,756,688
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GPCR short interestFrequently asked questions
What is the AI investment thesis for Structure Therapeutics Inc.?
Structure Therapeutics Inc. (GPCR) is a clinical-stage biopharmaceutical company developing oral small-molecule GPCR-targeted therapies for metabolic and endocrine disorders, with its lead candidate aleniglipron (GSBR-1290) in Phase 2 for obesity and overweight.
What is Structure Therapeutics Inc.'s lead drug candidate?
Structure Therapeutics Inc.'s most advanced tracked candidate is GSBR-1290 (Phase 2) for Type 2 diabetes mellitus (T2DM) and obesity.
Who is the CEO of Structure Therapeutics Inc.?
Dr. Raymond C. Stevens Ph.D. is the chief executive officer of Structure Therapeutics Inc. (GPCR).
Where is Structure Therapeutics Inc. headquartered?
Structure Therapeutics Inc. (GPCR) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Structure Therapeutics Inc. focus on?
Structure Therapeutics Inc. develops therapies across Oncology, Gene Therapy, Neurology, Immunology, Cardiovascular, Metabolic, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.